BioNTech

The spread of new strains raises new questions as two COVID-19 vaccines continue their rollout across the U.S. and another vaccine candidate preps for regulatory review. Here's what you need to know.

The new deal effectively doubles the federal government's order from the company. Pfizer said the U.S. government has agreed to pay $1.95 billion for the additional doses.

The Food and Drug Administration greenlights the biotech firm's vaccine for emergency use in the U.S. The move bolsters a vast inoculation effort that's already underway.

In a survey by the Kaiser Family Foundation, 71% of respondents said they would definitely or probably get inoculated — a significant leap over the 63% who said so in an August/September poll.

Pfizer and BioNTech's vaccine is the first to receive an emergency authorization from the Food and Drug Administration. Officials say it may be ready for widespread inoculations within days.

The vaccine produced by Pfizer and BioNTech is the first to be authorized by Canadian health officials. The decision makes Canada just the third country in the world to grant such an authorization.